We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Edwards Lifesciences, DexCom, Twitter, Cigna Corp and Restaurant Brands
Read MoreHide Full Article
For Immediate Release
Chicago, IL – October 18, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Edwards Lifesciences Corp. (EW - Free Report) , DexCom, Inc. (DXCM - Free Report) , Twitter, Inc. , Cigna Corporation (CI - Free Report) and Restaurant Brands International Inc. (QSR - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Analyst Reports for Edwards Lifesciences, DexCom and Twitter
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including Edwards Lifesciences, DexCom and Twitter. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of Edwards Lifesciences have outperformed the Zacks Medical Instruments industry in the year to date period (+19.1% vs. +6.5%). The Zacks analyst believes that the huge untapped potential in emerging markets will act as a positive catalyst for Edwards Lifesciences. The company is consolidating its foothold across all its operating businesses through strong pipeline development.
Strong adoption of the SAPIEN 3 Ultra platform and the PASCAL system across Europe is another positive. The solid demand for the company’s products used in high-risk surgeries is impressive too. Stiff competition in the THV business, however, continues to ail the company. Persistent forex woes are also a concern.
DexCom shares have gained +35.7% over the past year against the Zacks Medical Instruments industry’s gain of +6.6%. The Zacks analyst believes that a strong product portfolio, collaborative agreements with several companies and focus on international markets are key catalysts for growth.
DexCom’s Sensor and other revenue arm's contribution, and domestic and international revenue growth were key catalysts in second-quarter 2021. The company made continued advancements with respect to key strategic objectives and ended the quarter with new patient additions. Intensifying competition, entry of new products, reimbursement risks, supply constraints and working capital problems are some of the major concerns.
Shares of Twitter have lost -10.9% over the past six months against the Zacks Internet Software industry’s loss of -7%, however, things seem to be improving for the company. The Zacks analyst believes that the company’s initiatives to add features and focus on effectively tackling abuse issues are helping it expand its monetized user base.
Twitter is, however, suffering from stiff competition for ad dollars from the likes of Facebook and Google. Rising investments on international expansion, product innovation and marketing & sales are also expected to hurt profitability in the near term.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Edwards Lifesciences, DexCom, Twitter, Cigna Corp and Restaurant Brands
For Immediate Release
Chicago, IL – October 18, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Edwards Lifesciences Corp. (EW - Free Report) , DexCom, Inc. (DXCM - Free Report) , Twitter, Inc. , Cigna Corporation (CI - Free Report) and Restaurant Brands International Inc. (QSR - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Analyst Reports for Edwards Lifesciences, DexCom and Twitter
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including Edwards Lifesciences, DexCom and Twitter. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of Edwards Lifesciences have outperformed the Zacks Medical Instruments industry in the year to date period (+19.1% vs. +6.5%). The Zacks analyst believes that the huge untapped potential in emerging markets will act as a positive catalyst for Edwards Lifesciences. The company is consolidating its foothold across all its operating businesses through strong pipeline development.
Strong adoption of the SAPIEN 3 Ultra platform and the PASCAL system across Europe is another positive. The solid demand for the company’s products used in high-risk surgeries is impressive too. Stiff competition in the THV business, however, continues to ail the company. Persistent forex woes are also a concern.
(You can read the full research report on Edwards Lifesciences here >>>)
DexCom shares have gained +35.7% over the past year against the Zacks Medical Instruments industry’s gain of +6.6%. The Zacks analyst believes that a strong product portfolio, collaborative agreements with several companies and focus on international markets are key catalysts for growth.
DexCom’s Sensor and other revenue arm's contribution, and domestic and international revenue growth were key catalysts in second-quarter 2021. The company made continued advancements with respect to key strategic objectives and ended the quarter with new patient additions. Intensifying competition, entry of new products, reimbursement risks, supply constraints and working capital problems are some of the major concerns.
(You can read the full research report on DexCom here >>>)
Shares of Twitter have lost -10.9% over the past six months against the Zacks Internet Software industry’s loss of -7%, however, things seem to be improving for the company. The Zacks analyst believes that the company’s initiatives to add features and focus on effectively tackling abuse issues are helping it expand its monetized user base.
Twitter is, however, suffering from stiff competition for ad dollars from the likes of Facebook and Google. Rising investments on international expansion, product innovation and marketing & sales are also expected to hurt profitability in the near term.
(You can read the full research report on Twitter here >>>)
Other noteworthy reports we are featuring today include Cigna Corp and Restaurant Brands.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.